ProEncia Biotechnology

ProEncia Biotechnology is a Minnesota-based biotech startup developing novel, non-invasive therapeutics and prophylactic products for periodontal disease. The company is focused on addressing the underlying inflammatory and pathogenic drivers of gum disease rather than only treating symptoms. Its pipeline is described as patent-pending and includes products intended for patients across the full spectrum of disease severity, including gingivitis and periodontitis. ProEncia positions its approach at the intersection of oral health and chronic inflammatory disease biology, with plans to develop, commercialize, and license its products. The company closed a pre-seed financing round in May 2026 to advance its next-generation periodontal disease treatment platform.